Carmustina Hikma

Carmustine Hikma is a chemotherapy medication used to treat certain types of cancer. This intravenous drug is manufactured by Hikma Farmacêutica (Portugal), S.A. and is available in the EU.

Carmustine Hikma is primarily used in the treatment of brain tumors, such as glioblastoma multiforme and brain metastases. It may also be used in combination with other chemotherapy drugs for certain types of cancer. The medication works by interfering with the growth of cancer cells, helping to slow or stop their spread.

Common effects of Carmustine Hikma may include nausea, vomiting, and fatigue. Some patients may also experience hair loss, loss of appetite, and changes in blood cell counts. These effects can vary in severity and may require medical attention if they become severe or persistent.

Carmustine Hikma should be handled with care, as it is a potent chemotherapy drug. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should also be monitored regularly for any signs of adverse reactions or changes in their condition.

Carmustine Hikma may interact with other medications, including those that suppress the immune system or affect blood cell counts. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol should be avoided while using this medication, as it can increase the risk of side effects.